* ST eye medicine (stock code: 600671) is a company mainly engaged in pharmaceutical manufacturing, drug distribution, traditional Chinese medicine diagnosis and treatment and big health. Its products include amoxicillin clavulanate potassium tablets, Dendrobium candidum health products and so on, and the sales areas are mainly concentrated in East and South China. However, judging from its 2023 report, the company faces some financial pressure.

First of all, in terms of asset-liability ratio, the asset-liability ratio of * ST increased from 98.51% at the beginning of the period to 107.47% at the end of the period, indicating that the company's debt pressure increased, and the debt exceeded the total assets, which posed a certain pressure on the company's operation.

Secondly, the company's net assets decreased from 4.48 million yuan at the beginning of the period to-192 million yuan at the end of the period, indicating that the company incurred a loss in the course of operation and decreased its capital accumulation capacity. At the same time, the total assets of the company dropped from 300 million yuan at the beginning of the period to 257 million yuan at the end of the period, which further confirmed the operating pressure of the company.

Thirdly, in terms of profit, the company's gross profit margin increased from 20.17% in the same period last year to 22.59% in the reporting period, indicating that the company's profits from selling products have increased. However, as the company's operating income decreased during the reporting period, from 519 million yuan to 51 million yuan, the company's overall profit level has not been improved.

In addition, the company's goodwill was 2.2 million yuan at the beginning and end of the period, which remained unchanged, indicating that the company did not engage in significant mergers and acquisitions during the reporting period.

Generally speaking, * ST is facing certain operating pressure in the first half of 2023. The increase in asset-liability ratio, the decrease in net assets and the decline in operating income all reflect the company's operational difficulties. Therefore, when investors consider investing in * ST eye medicine, they need to fully consider these factors and make a careful decision.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.